Otonomy Initiates Patient Enrollment in U.S. Phase 3 Clinical Trial of OTO-104 in Meniere's Disease
SAN DIEGO, Nov. 18, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear, today announced the …